{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hahn F"],"funding":["Deutsche Forschungsgemeinschaft","Wilhelm Sander-Stiftung","Johannes und Frieda Marohn-Stiftung"],"pagination":["E1394"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7762174"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(12)"],"pubmed_abstract":["The ongoing pandemic spread of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) demands skillful strategies for novel drug development, drug repurposing and cotreatments, in particular focusing on existing candidates of host-directed antivirals (HDAs). The developmental drug IMU-838, currently being investigated in a phase 2b trial in patients suffering from autoimmune diseases, represents an inhibitor of human dihydroorotate dehydrogenase (DHODH) with a recently proven antiviral activity in vitro and in vivo. Here, we established an analysis system for assessing the antiviral potency of IMU-838 and DHODH-directed back-up drugs in cultured cell-based infection models. By the use of SARS-CoV-2-specific immunofluorescence, Western blot, in-cell ELISA, viral yield reducti"],"journal":["Viruses"],"pubmed_title":["IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro."],"pmcid":["PMC7762174"],"funding_grant_id":["MA/SBT 2018.121.1","Alz/Iko-Hahn/2019","MA 1289/7-3"],"pubmed_authors":["Hahn F","Muehler A","Uberla K","Peelen E","Dobler G","Vitt D","Hurst B","Hage S","Peter AS","Julander J","Kohlhof H","Jack HM","Ptak R","Groppel M","Fuchs J","Ruzsics Z","Marschall M","Wangen C"],"additional_accession":[]},"is_claimable":false,"name":"IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.","description":"The ongoing pandemic spread of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) demands skillful strategies for novel drug development, drug repurposing and cotreatments, in particular focusing on existing candidates of host-directed antivirals (HDAs). The developmental drug IMU-838, currently being investigated in a phase 2b trial in patients suffering from autoimmune diseases, represents an inhibitor of human dihydroorotate dehydrogenase (DHODH) with a recently proven antiviral activity in vitro and in vivo. Here, we established an analysis system for assessing the antiviral potency of IMU-838 and DHODH-directed back-up drugs in cultured cell-based infection models. By the use of SARS-CoV-2-specific immunofluorescence, Western blot, in-cell ELISA, viral yield reducti","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Dec","modification":"2026-05-02T16:58:09.232Z","creation":"2021-02-20T17:12:12Z"},"accession":"S-EPMC7762174","cross_references":{"pubmed":["33291455"],"doi":["10.3390/v12121394"]}}